ITOS News and Press, iTeos Therapeutics Inc. From 02/10/24

2024-02-10 12:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-30 10:22:11 ET More on Arcus Biosciences Arcus Biosciences: Showing There Might Be Something To TIGIT After All Arcus Biosciences' Oncology Odyssey: The Domvanalimab Journey Arcus Biosciences, Inc. (RCUS) Q3 2023 Earnings Call Transcript Gilead invest...

2024-01-10 08:01:12 ET Summary Data readout from phase 2 GALAXIES Lung-201 study, using belrestotug in combination with dostarlimab to treat patients with 1st-line advanced/metastatic NSCLC, expected 2024. The global non-small cell lung cancer market is expected to reach $36.9 bil...

2024-01-09 07:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-08 14:03:59 ET More on iTeos Therapeutics iTeos Therapeutics: Trying Hard Where The Big Guys Might Still Fail Seeking Alpha’s Quant Rating on iTeos Therapeutics Historical earnings data for iTeos Therapeutics Financial information for iTeos The...

- TIGIT program clinical data readouts anticipated in 2024, including two Phase 2 trials assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC - Adenosine portfolio clinical data readouts anticipated in second half of 2024, including inupadenant’s Phase 2 A2A-005 and EOS-984...

WATERTOWN, Mass. and GOSSELIES, Belgium, Jan. 03, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel Det...

2023-12-15 04:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 21, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immune-oncology therapeutics for patients, today announced that management...

iTeos Therapeutics Inc. (ITOS) is expected to report $-1.2 for Q3 2023